Messineo, Ludovico http://orcid.org/0000-0002-4142-9124
Perger, Elisa
Corda, Luciano
Joosten, Simon A.
Fanfulla, Francesco
Pedroni, Leonardo
Terrill, Philip I.
Lombardi, Carolina
Wellman, Andrew
Hamilton, Garun S.
Malhotra, Atul
Vailati, Guido
Parati, Gianfranco
Sands, Scott A.
Article History
Received: 23 April 2021
Accepted: 6 June 2021
First Online: 14 June 2021
Declarations
:
: This study was approved by the Italian Auxologico Institute Ethics Committee (number: 2020_04_03_03) on April 3rd, 2020, which was the reference center for recruitment of COVID-19 patients, and by the Monash Health HREC (number: RES-20-0000-264A) on April 29th, 2020, which was the main reference for recruitment of healthy individuals. The study was also approved by the Brescia local Ethics Committee (number: 4068) on April 17th, 2020 and Pavia local Ethics Committee (number: 2412) on April 20th, 2020. All participants provided verbal or written informed consent upon enrolment (the study was exempted from written consent in some centers to limit the spread of the infection). The study conformed to the standards set by the latest revision of the Declaration of Helsinki. This study also adhered to both STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) and TRIPOD (Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis) reporting guidelines.
: NA.
: AW works as a consultant for Apnimed, Nox, Inspire, and Somnifix. He has received grants from Sanofi and Somnifix. He also has a financial interest in Apnimed Corp., a company developing pharmacologic therapies for sleep apnea. AW interests were reviewed and are managed by Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies. SS reports grants and personal fees from Apnimed, personal fees from Nox Medical, personal fees from Merck, personal fees from Inspire, grants from Prosomnus, grants from Dynaflex, outside the submitted work. In addition, SS has a patent pending related to wearable oximetry technology for sleep apnea diagnosis/phenotyping, unrelated to breath-holding. GH reports non-financial support from Resmed, non-financial support from Philips Respironics, non-financial support from Air Liquide Healthcare, outside the submitted work. AM reports income related to medical education from Merck and Livanova; ResMed provided a philanthropic donation to UC San Diego. LM, EP, LC SJ, FF, LP, PT, CL, GV, GP have no conflicts of interest to disclose.